RE:Unimpressive Q3 - Still WaitingI'm actually a bit surprised by the market's reaction. Book value increased to roughly $7.70/share. It's the 3rd straight quarter of operating profit which is the most important metric as the investment in funds vary a lot to swing Net Income. The revaluation for Synergy is great but we'll see where its trading in 6 months after lock-up and what Knight chooses to do with that investment. The pipeline continues to move along.
Lenvima having more competition is the bad news. That is the nature of the business which isn't new.
Anything else you guys are seeing to warrant this selloff?